Pharmacokinetics of ciprofloxacin after oral and parenteral administration.
about
Absolute oral bioavailability of ciprofloxacinComparative in vitro activities of ciprofloxacin and other 4-quinolones against Mycobacterium tuberculosis and Mycobacterium intracellulare.Complicated catheter-associated urinary tract infections due to Escherichia coli and Proteus mirabilisOrganic anion transporter 3 (oat3/slc22a8) interacts with carboxyfluoroquinolones, and deletion increases systemic exposure to ciprofloxacinPharmacokinetics of ciprofloxacin in cystic fibrosis.An evaluation of ciprofloxacin pharmacokinetics in critically ill patients undergoing continuous veno-venous haemodiafiltration.Pharmacokinetics of levofloxacin and ciprofloxacin during continuous renal replacement therapy in critically ill patientsBiofilms and their role in infections in urology.Commonly used antibacterial and antifungal agents for hospitalised paediatric patients: implications for therapy with an emphasis on clinical pharmacokinetics.Pharmacodynamic evaluation of the intracellular activities of antibiotics against Staphylococcus aureus in a model of THP-1 macrophages.Effect of probenecid on the distribution and elimination of ciprofloxacin in humans.Antibiotic therapy in aging patients.Assessment of the role of renal organic anion transporters in drug-induced nephrotoxicity.Pharmacokinetics and metabolism of intravenous and oral fleroxacin in subjects with normal and impaired renal function and in patients on continuous ambulatory peritoneal dialysis.Pharmacokinetics of FCE 22891, a new oral penem.Pharmacokinetics and serum bactericidal activities of quinolones in combination with clindamycin, metronidazole, and ornidazole.Steady-state pharmacokinetics of intravenous and oral ciprofloxacin in elderly patients.Ciprofloxacin pharmacokinetics in patients with normal and impaired renal functionPharmacokinetics of ofloxacin after parenteral and oral administrationEffect of dose on serum pharmacokinetics of intravenous ciprofloxacin with identification and characterization of extravascular compartments using noncompartmental and compartmental pharmacokinetic models.Randomized, double-blind comparison of ciprofloxacin and trimethoprim-sulfamethoxazole for complicated urinary tract infectionsThe fluoroquinolones: pharmacology, clinical uses, and toxicities in humans.Ciprofloxacin therapy for Mediterranean spotted feverComparison of high-pressure liquid chromatography and microbiological assay for the determination of biliary elimination of ciprofloxacin in humans.In vitro susceptibility of Rickettsia conorii to ciprofloxacin as determined by suppressing lethality in chicken embryos and by plaque assayTissue penetration of ciprofloxacin after single and multiple doses.Pharmacokinetics and pharmacodynamics of ciprofloxacin in cystic fibrosis patients.Evaluation of the efficacy of ciprofloxacin against Streptococcus pneumoniae by using a mouse protection model.Sequential antibiotic therapy: Effective cost management and patient care.Effect of linezolid on the 50% lethal dose and 50% protective dose in treatment of infections by Gram-negative pathogens in naive and immunosuppressed mice and on the efficacy of ciprofloxacin in an acute murine model of septicemia.Ciprofloxacin biliary disposition in cholecystectomised patients with special references to HPLC and bioassay data.Steady-state pharmacokinetics of ciprofloxacin in plasma from patients with nosocomial pneumonia: penetration of the bronchial mucosa.In vitro activity of the two new 4-quinolones A56619 and A56620 against Neisseria gonorrhoeae, Chlamydia trachomatis, Mycoplasma hominis, Ureaplasma urealyticum and Gardnerella vaginalis.Fluoroquinolone disposition: identification of the contribution of renal secretory and reabsorptive drug transporters.Pharmacokinetics of ciprofloxacin with reference to other fluorinated quinolones.Preparation of polylactic acid microcapsules containing ciprofloxacin.A case study of in silico modelling of ciprofloxacin hydrochloride/metallic compound interactionsPharmacokinetics of intravenous finafloxacin in healthy volunteers.Continuous Intestinal Absorption Model Based on the Convection-Diffusion Equation.Ciprofloxacin: chemistry, mechanism of action, resistance, antimicrobial spectrum, pharmacokinetics, clinical trials, and adverse reactions.
P2860
Q24685241-371136AB-9BF9-483E-8EAE-3994CFE5A994Q28360184-08F9B2CD-3D7B-48FC-BB5B-A76167CF44B9Q30491878-06B621CD-5439-4CC2-96C9-C54DEC449863Q33658156-1FD6841E-7650-41E0-B588-1B26BBE4FAC7Q33741046-0479AB6C-FFBA-4C9B-BE17-E71E359FAD63Q33982009-75EEEF79-3114-4C6B-82D8-D745548FE7BAQ33983228-E4701C88-AD76-41B2-B777-489541D02B22Q34078568-CFBC8D3C-BD3F-4CBC-BD00-1F805E9529E6Q34437719-7587B6D2-3E69-4960-A2B2-82AE7A06D1D6Q34509728-7DC6D4C3-E075-4969-AEA3-599E380A1028Q34720221-56932507-EDDD-4D80-8FCF-22DE754BC844Q35119901-87A898CB-F4DF-4C01-9174-A5F888C3BF0BQ35155913-55561CA1-89EE-4B9D-9F84-9CBC4479F8A5Q35245010-9AD39DFE-9D77-47EF-B632-4C7590D0ADE4Q35258286-C5D0E830-EB7A-4661-BB45-8F6ABEBB91A2Q35285981-F3F58C1C-A14D-44AB-B5C4-2EC6505081B2Q35359695-ED1AE6F1-B0B9-48B6-A404-809E525C69FAQ35539825-1FCC4F72-47C4-4201-8D13-969A5AD8B553Q35541436-20DA7BB8-D866-41E2-BF39-55C250D47A5BQ35543462-52ABCF14-B005-4D25-9471-19030FA9C5F0Q35563727-6C09B335-A22C-4E57-876F-79B281A945FDQ35572870-0D97768B-5068-43B0-9FC1-E6C1220A0108Q35575365-AC2C9ACE-1DF2-4EF3-8653-96C500A4060DQ35646379-D26E7A6A-C94E-4C43-8483-39158477FF95Q35648699-5D59A9AE-3B63-49DE-BB21-C23078054AAAQ35649002-B84760F9-3A4D-47C6-B22B-F6BF73AE7ED2Q35651376-4B924562-BCE6-498B-8C9E-6DC549AB62B6Q35808500-B647B3D0-DD28-4130-82C2-32E591A84FEDQ35893020-08F324A5-B3E2-43DA-A8AF-2038B098BA8BQ36172366-6DE69DD1-57A0-4708-B64F-3A88667A05DFQ36474398-F797031D-51F0-4A06-8226-FAC534E7BE16Q36757441-3CC25A6C-DAEC-4FBD-AA7D-A394A227439CQ37902572-E78ACB6C-2ADC-4594-9431-13EDDF440CC8Q37995676-D776D7F3-47F4-4096-B905-9AB6A786C4D0Q38271416-796936AE-DDC8-43C3-83C0-0454D6BBA9A3Q38551254-EB91EA3B-90A9-4AAF-91E1-482FD5D99C95Q38555068-A6DB2870-2C2A-4DDD-A7BC-C3CAE3C4BC82Q38636236-7D414BA4-5C05-49AF-A6A0-D4424E8FEA08Q38677027-51232908-AE41-4CBB-99CF-D2FC115ECCE2Q39214819-92DB8229-41BF-4CE5-8690-B948CB2F89CD
P2860
Pharmacokinetics of ciprofloxacin after oral and parenteral administration.
description
1985 nî lūn-bûn
@nan
1985年の論文
@ja
1985年論文
@yue
1985年論文
@zh-hant
1985年論文
@zh-hk
1985年論文
@zh-mo
1985年論文
@zh-tw
1985年论文
@wuu
1985年论文
@zh
1985年论文
@zh-cn
name
Pharmacokinetics of ciprofloxacin after oral and parenteral administration.
@ast
Pharmacokinetics of ciprofloxacin after oral and parenteral administration.
@en
type
label
Pharmacokinetics of ciprofloxacin after oral and parenteral administration.
@ast
Pharmacokinetics of ciprofloxacin after oral and parenteral administration.
@en
prefLabel
Pharmacokinetics of ciprofloxacin after oral and parenteral administration.
@ast
Pharmacokinetics of ciprofloxacin after oral and parenteral administration.
@en
P2093
P2860
P356
P1476
Pharmacokinetics of ciprofloxacin after oral and parenteral administration.
@en
P2093
P2860
P304
P356
10.1128/AAC.27.3.375
P407
P577
1985-03-01T00:00:00Z